Search for Topics:
Title/Keyword
Journal
Submission Status
Category
 
 
Topics
Porphyrinoids Photosensitizers for Biomedical Applications
Edit a Topic

Topic Menu

► Topic Menu

Topic Editors

Institute of Electronics, Bulgarian Academy of Sciences, 1784 Sofia, Bulgaria
Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria
Dr. Vesselin Kussovski
The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria
share announcement

Porphyrinoids Photosensitizers for Biomedical Applications

Abstract submission deadline
closed (28 February 2023)
Manuscript submission deadline
closed (30 April 2023)
Viewed by
2567

Topic Information

Dear Colleagues,

The rapid spread of problems associated with drug resistance towards the present usage of chemotherapeutics necessitates the research and development of new natural and synthetic photosensitive compounds (photosensitizers) for biomedical applications. Well-known porphyrinoids such as porphyrins, phthalocyanines, and their related derivatives are of interest for the development of more effective original photosensitive molecules. Attempts to combine the best of their properties aim to facilitate optical diagnosis by fluorescence and local treatment owning to photosensitization. The curative method known as photodynamic therapy (PDT) has photodynamic action and has received research interest for more than a century. The scope of the present Topic is to collect the best of the recent developments made in the use of porphyrinoid photosensitizers in synthetic schemes, chemical and optical characterization, and the evaluation of photobiological properties as new-generation photosensitizers. We seek to collect novel studies conducted in the area of photochemistry science, as well as in photobiology research investigations, evaluations of their efficacy in PDT and fluorescent diagnosis, and in their application as theranostics agents. Original papers from prominent colleagues working in multidisciplinary areas of chemistry, biology, and biophysics will be highly appreciated.

Dr. Ivan Angelov
Dr. Vanya N. Mantareva
Dr. Vesselin Kussovski
Topic Editors

Keywords

  • photosensitizers
  • porphyrins
  • phthalocyanines
  • mechanisms of photosensitization
  • photophysics
  • photochemistry
  • photobiology
  • optical diagnosis
  • photodynamic therapy
  • theranostics

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Biology
biology 		5.168 2.8 2012 16.1 Days 2200 CHF
Biomolecules
biomolecules 		6.064 5.7 2011 16.6 Days 2300 CHF
Current Issues in Molecular Biology
cimb 		2.976 2.7 1999 17.2 Days 2000 CHF
International Journal of Molecular Sciences
ijms 		6.208 6.9 2000 15.9 Days 2500 CHF
Pharmaceuticals
pharmaceuticals 		5.215 4.0 2004 15.6 Days 2200 CHF

Preprints is a platform dedicated to making early versions of research outputs permanently available and citable. MDPI journals allow posting on preprint servers such as Preprints.org prior to publication. For more details about reprints, please visit https://www.preprints.org.

Published Papers (2 papers)

Order results
Result details
Journals
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
get_app
Article
Alteration of Mesenchymal Stem Cells Isolated from Glioblastoma Multiforme under the Influence of Photodynamic Treatment
by
Kalina Tumangelova-Yuzeir
,
Krassimir Minkin
,
Ivan Angelov
,
Ekaterina Ivanova-Todorova
,
Ekaterina Kurteva
,
Georgi Vasilev
,
Jeliazko Arabadjiev
,
Petar Karazapryanov
,
Kaloyan Gabrovski
,
Lidia Zaharieva
,
Tsanislava Genova
and
Dobroslav Kyurkchiev
Curr. Issues Mol. Biol. 2023, 45(3), 2580-2596; https://doi.org/10.3390/cimb45030169 - 21 Mar 2023
Viewed by 1203
Abstract
The central hypothesis for the development of glioblastoma multiforme (GBM) postulates that the tumor begins its development by transforming neural stem cells into cancer stem cells (CSC). Recently, it has become clear that another kind of stem cell, the mesenchymal stem cell (MSC), [...] Read more.
The central hypothesis for the development of glioblastoma multiforme (GBM) postulates that the tumor begins its development by transforming neural stem cells into cancer stem cells (CSC). Recently, it has become clear that another kind of stem cell, the mesenchymal stem cell (MSC), plays a role in the tumor stroma. Mesenchymal stem cells, along with their typical markers, can express neural markers and are capable of neural transdifferentiation. From this perspective, it is hypothesized that MSCs can give rise to CSC. In addition, MSCs suppress the immune cells through direct contact and secretory factors. Photodynamic therapy aims to selectively accumulate a photosensitizer in neoplastic cells, forming reactive oxygen species (ROS) upon irradiation, initiating death pathways. In our experiments, MSCs from 15 glioblastomas (GB-MSC) were isolated and cultured. The cells were treated with 5-ALA and irradiated. Flow cytometry and ELISA were used to detect the marker expression and soluble-factor secretion. The MSCs’ neural markers, Nestin, Sox2, and glial fibrillary acid protein (GFAP), were down-regulated, but the expression levels of the mesenchymal markers CD73, CD90, and CD105 were retained. The GB-MSCs also reduced their expression of PD-L1 and increased their secretion of PGE2. Our results give us grounds to speculate that the photodynamic impact on GB-MSCs reduces their capacity for neural transdifferentiation. Full article
(This article belongs to the Topic Porphyrinoids Photosensitizers for Biomedical Applications)
►▼ Show Figures

Figure 1

get_app
Article
The In Vitro and In Vivo Anticancer Effect of Photomed for Photodynamic Therapy: Comparison with Photofrin and Radachlorin
by
Jieun Kim
,
Johyun Kim
,
Heewon Yoon
,
Yoon-Jee Chae
,
Kiyon Rhew
and
Ji-Eun Chang
Curr. Issues Mol. Biol. 2023, 45(3), 2474-2490; https://doi.org/10.3390/cimb45030162 - 17 Mar 2023
Viewed by 353
Abstract
To overcome the limitation of conventional cancer treatments, photodynamic therapy (PDT) has been introduced as another treatment option. PDT provides a non-invasive, non-surgical way with reduced toxicity. To improve the antitumor efficacy of PDT, we synthesized a novel photosensitizer, a 3-substituted methyl pyropheophorbide-a [...] Read more.
To overcome the limitation of conventional cancer treatments, photodynamic therapy (PDT) has been introduced as another treatment option. PDT provides a non-invasive, non-surgical way with reduced toxicity. To improve the antitumor efficacy of PDT, we synthesized a novel photosensitizer, a 3-substituted methyl pyropheophorbide-a derivative (Photomed). The purpose of the study was to evaluate the antitumor effect of PDT with Photomed comparing with the clinically approved photosensitizers Photofrin and Radachlorin. The cytotoxicity assay against SCC VII cells (murine squamous cell carcinoma) was performed to determine whether Photomed is safe without PDT and whether Photomed is effective against cancer cells with PDT. An in vivo anticancer efficacy study was also performed using SCC VII tumor-bearing mice. The mice were divided into small-tumor and large-tumor groups to identify whether Photomed-induced PDT is effective for not only small tumors but also large tumors. From in vitro and in vivo studies, Photomed was confirmed to be (1) a safe photosensitizer without laser irradiation, (2) the most effective photosensitizer with PDT against cancers compared to Photofrin and Radachlorin and (3) effective with PDT in treating not only small tumors but also large tumors. In conclusion, Photomed may contribute as a novel, potential photosensitizer for use in PDT cancer treatment. Full article
(This article belongs to the Topic Porphyrinoids Photosensitizers for Biomedical Applications)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop